The Synodos for NF2 consortium of the Children’s Tumor Foundation (CTF) today published its first set of results and released its second set of data in the leading scientific journal PLOS ONE. Synodos is the Foundation’s innovative team science collaborative that brings researchers, clinicians and patients together in a shared data environment, in order to develop treatments for NF patients at an accelerated pace. Established in 2014, the $3 million project is a combined effort among 12 leading research labs at 8 institutions.
The Synodos for NF2 team released its first set of results and data in the scientific journal PLOS ONE, entitled Traditional and Systems Biology Based Drug Discovery for the Rare Tumor Syndrome Neurofibromatosis Type 2. In line with the Foundation’s principles of open-access and data sharing, the journal is making the full article available to all, with immediate access to the data.
The primary aim of the Synodos for NF2 team was to find treatments that could be used for both meningioma and schwannoma by using a drug discovery approach of selecting mechanistically relevant compounds. The team integrated innovative research approaches such as Next Generation Sequencing (NGS) and Kinome profiling. These two techniques allow analysis of
Article originally posted at